D-Pressin Nasal Spray 5ml (Desmopressin)

Product Overview

D‑Pressin Nasal Spray 5ml is a prescription‑grade medication that contains desmopressin, a synthetic analog of the hormone vasopressin. It is formulated for intranasal administration and is indicated for the treatment of nocturnal enuresis (bed‑wetting) in children and adults, as well as central diabetes insipidus. United Biotech, a reputable manufacturer with a track record in endocrinology products, packages each unit in a 5ml sterile bottle with a convenient dropper tip. The product is supplied in pack sizes of 1, 3, or 6 sprays, allowing patients to choose the quantity that best fits their therapy plan. Shipping typically occurs within 6 to 15 days, and the item is classified under the Diabetes Care category on most e‑commerce platforms.

What is D‑Pressin Nasal Spray?

Desmopressin, the active ingredient in D‑Pressin, mimics the antidiuretic hormone (ADH) that reduces urine production by acting on the V2 receptors of the renal collecting ducts. When sprayed into the nasal cavity, the drug is rapidly absorbed into the systemic circulation, reaching peak plasma concentrations within 30‑60 minutes. This mechanism helps to concentrate urine and reduce the frequency of nocturnal voiding episodes. The medication is classified as a synthetic peptide and is listed in the United States Pharmacopeia (USP) monograph for desmopressin nasal spray. Clinicians consider it a first‑line option for patients who require a non‑oral route or who have difficulty swallowing tablets.

Uses and Benefits

The primary clinical uses of D‑Pressin Nasal Spray are the reduction of nighttime urine volume in patients with nocturnal enuresis and the management of chronic diabetes insipidus. In pediatric populations, clinical trials have demonstrated a 50‑70% decrease in wet nights after two weeks of consistent use. Adults with diagnosed central diabetes insipidus benefit from a stable water balance, decreased thirst, and fewer episodes of polyuria. Because the spray is administered directly to the nasal mucosa, it bypasses the gastrointestinal tract, leading to a quicker onset of action compared with oral tablets. Additionally, the dosing schedule is typically once or twice daily, which improves adherence and reduces the likelihood of missed doses. The product is also favored for its minimal impact on blood pressure and electrolytes when used at recommended doses.

How It Works

Desmopressin exerts its pharmacological effect by binding to V2 receptors on the basolateral membrane of principal cells in the kidney’s collecting ducts. This binding triggers the insertion of aquaporin‑2 water channels into the apical membrane, facilitating water reabsorption and concentrating urine. The result is a marked reduction in nocturnal polyuria, which translates into fewer wet beds for children and decreased fluid intake during the day for adults with diabetes insipidus. The drug’s half‑life is approximately 1–2 hours, but its renal effects can persist for up to 8–12 hours, providing sustained antidiuretic activity. Because desmopressin is peptide‑based, it is susceptible to enzymatic degradation, which is why the nasal spray formulation incorporates a stabilizer to preserve potency until administration.

Dosage Guidelines

Dosage of D‑Pressin Nasal Spray is individualized based on patient age, weight, and clinical response. For children aged 6 years and older, the usual starting dose is one spray (approximately 0.5 µg desmopressin) into each nostril once daily, preferably at bedtime. Adults with diabetes insipidus may require a higher dose, often 1–2 sprays per nostril once daily, depending on serum osmolality and urine output. Dose adjustments are made after a minimum of 7 days of therapy, with increments of 0.5 µg not exceeding a maximum of 4 sprays per day (2 per nostril). Patients should be instructed to blow their nose gently before each use, then close one nostril and insert the tip into the other, delivering a single spray while inhaling gently. The spray should not be shared between users to avoid cross‑contamination. If a dose is missed, it should be taken as soon as remembered unless it is close to the time of the next scheduled dose; in that case, the missed dose should be skipped and the regular schedule resumed. Over‑dosage can lead to hyponatremia, so patients must adhere strictly to the prescribed amount.

Side Effects

Most patients tolerate D‑Pressin Nasal Spray well, but some may experience mild adverse reactions. Common side effects include headache, nasal irritation, epistaxis (nosebleeds), and a transient metallic taste. Less frequently, users may report abdominal discomfort, flushing, or mild dizziness. In rare cases, a serious electrolyte imbalance, particularly hyponatremia, can occur, especially in elderly patients or those who are concurrently taking other medications that affect water balance. Signs of hyponatremia include nausea, headache, confusion, and in severe cases, seizures. If any of these symptoms develop, patients should discontinue use and seek medical attention promptly. Reporting adverse events to a healthcare provider or directly to the FDA’s MedWatch program is encouraged to support ongoing safety monitoring.

Warnings and Precautions

Before initiating therapy with D‑Pressin Nasal Spray, clinicians should evaluate a patient’s medical history for conditions that may increase the risk of fluid imbalance, such as heart failure, renal impairment, or syndrome of inappropriate antidiuretic hormone secretion (SIADH). Concomitant use of other antidiuretic agents or medications that cause water retention (e.g., certain antidepressants) should be reviewed. Patients should avoid consuming excessive amounts of fluids close to bedtime, as this can counteract the drug’s effect and increase the risk of nocturnal polyuria. Caution is advised for pregnant or lactating women, as the safety of desmopressin during pregnancy has not been fully established. The medication should be stored at room temperature, protected from moisture and direct sunlight, and kept out of reach of children. If a patient experiences an allergic reaction characterized by rash, swelling, or difficulty breathing, immediate medical care is required.

Frequently Asked Questions

• What is the active ingredient in D‑Pressin Nasal Spray? The active ingredient is desmopressin, a synthetic analog of vasopressin that reduces urine output.
• How quickly does the spray work? Most users notice a reduction in nighttime wetting within 3‑5 days of consistent use, with maximal effect observed after 1‑2 weeks.
• Can I use D‑Pressin if I have high blood pressure? Yes, desmopressin does not typically raise blood pressure, but patients with severe hypertension should discuss usage with their physician.
• Is the spray safe for children? Clinical studies support its use in children 6 years and older when prescribed by a healthcare professional.
• Where can I find more information about desmopressin? Detailed prescribing information is available from the FDA label, the National Institutes of Health (NIH) database, and MedlinePlus.

Related Products

• Desmopressin 120mcg (Generic)
• Desmopressin 0.2mg (Generic)
• Desmopressin 0.1mg (Generic)
• Desmopressin 60mcg (Generic)
• Minirin 0.1mg (Desmopressin)
• Desmopressin Nasal Spray 5 ml
• Minirin (Desmopressin)
• Minirin 0.2mg (Desmopressin)
• Minirin Nasal Spray (Desmopressin)
• Minirin Melt 120 mcg (Desmopressin)
• Minirin Melt 60mcg (Desmopressin)